Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation
- PMID: 34285344
- DOI: 10.1038/s41375-021-01351-w
Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation
Similar articles
-
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.Leukemia. 2024 Jun;38(6):1419-1422. doi: 10.1038/s41375-024-02251-5. Epub 2024 Apr 17. Leukemia. 2024. PMID: 38632315 Free PMC article. No abstract available.
-
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26. Br J Haematol. 2017. PMID: 29076142
-
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.Leukemia. 2021 Jun;35(6):1563-1570. doi: 10.1038/s41375-020-01056-6. Epub 2020 Oct 19. Leukemia. 2021. PMID: 33077866 Free PMC article.
-
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.Curr Res Transl Med. 2020 Jan;68(1):17-22. doi: 10.1016/j.retram.2019.12.001. Epub 2019 Dec 25. Curr Res Transl Med. 2020. PMID: 31882377 Review.
-
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL.Semin Hematol. 2024 Oct;61(5):314-320. doi: 10.1053/j.seminhematol.2024.08.004. Epub 2024 Aug 22. Semin Hematol. 2024. PMID: 39370355 Review.
Cited by
-
"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.Curr Treat Options Oncol. 2023 May;24(5):409-441. doi: 10.1007/s11864-023-01061-8. Epub 2023 Apr 3. Curr Treat Options Oncol. 2023. PMID: 37010679 Review.
-
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.Front Immunol. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235. eCollection 2022. Front Immunol. 2022. PMID: 36091028 Free PMC article. Review.
-
Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.Haematologica. 2025 Mar 1;110(3):562-575. doi: 10.3324/haematol.2024.286194. Haematologica. 2025. PMID: 39568419 Free PMC article. Review.
-
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.Blood Adv. 2022 Oct 11;6(19):5582-5588. doi: 10.1182/bloodadvances.2021006262. Blood Adv. 2022. PMID: 35446932 Free PMC article. No abstract available.
-
[The present and future of haploidentical hematopoietic stem cell transplantation in China].Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):625-628. doi: 10.3760/cma.j.cn121090-20240215-00061. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39231765 Free PMC article. Chinese.
References
-
- Wang Y, Liu Q-F, Lin R, Yang T, Xu Y-J, Mo X-D, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci. Bull. https://doi.org/10.1016/j.scib.2021.06.002 .
-
- Zhao X, Zhao X, Chen H, Qin Y, Xu L, Zhang X, et al. Comparative analysis of flow cytometry and RQ-PCR for the detection of minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:1936–43. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources